Press Release **For Immediate Dissemination**

Glenmark Pharmaceuticals in-licenses novel anti-TrkA antibody from Lay Line Genomics, Italy

- Glenmark receives the exclusive license to the monoclonal antibody BXL1H5, including the exclusive target license to commercialize monoclonal antibodies against TrkA receptor for pain.
- TrkA is a promising target and monoclonal antibodies specific for TrkA represent a first in class opportunity for the treatment of chronic pain. The pain market is estimated at USD 26 billion with a large unmet medical need for the treatment of chronic pain.
- BXL1H5 is a novel monoclonal antibody and will be developed by Glenmark's biologics R&D centre in Switzerland.

October 6, 2010 – Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announced today that it has been granted by Lay Line Genomics S.p.A. (LLG) an exclusive, worldwide license to LLG's entire intellectual property portfolio in the TrkA field. The licensed assets include BXL1H5 which is a novel monoclonal antibody that binds to TrkA receptors. This represents another first-in-class opportunity for Glenmark.

The deal is of specific significance, because Glenmark has not only in-licensed a preclinical, unique monoclonal antibody, but also has the sole and exclusive license to commercialize monoclonal antibodies against TrkA receptor for pain. Anti-TrkA which is a novel class of pain therapeutics has a central role in the pain mechanism and has the potential to address the unmet needs in pain therapy. Glenmark has gained significant expertise in developing monoclonal antibodies and also has rich experience in the pain therapeutic area. The development of this novel biologic entity (NBE) will be done by Glenmark's biologic R&D centre in Switzerland, which is focused on discovering and developing NBEs.

Commenting on this deal, Mr. Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals mentioned "We are excited to have been granted the sole and exclusive license to commercialize monoclonal antibodies against the TrkA receptor for pain. We are enthusiastic about the addition of BXL1H5 to the Glenmark discovery pipeline. Glenmark will leverage its expertise in monoclonal antibodies to progress BXL1H5 rapidly into clinical development."

"We are extremely pleased that Glenmark Pharmaceuticals shares our excitement for the anti-TrkA project and look forward to the next stages of development with great enthusiasm" **said Ennio Esposito, Sole Director at Lay Line Genomics(LLG), Italy**

The pain market generated sales in excess of $25 billion and more than 102 million individuals suffered from chronic pain across the seven major markets. Less than 30% of patients with chronic pain obtain adequate pain relief and efficacy remains the largest unmet need in chronic pain treatment.

Glenmark will undertake further development and commercialization of BXL1H5 in exchange for an undisclosed upfront and milestone payments to Lay Line Genomics.

About TrkA and BXL1H5

TrkA represents a highly interesting target for developing treatments against chronic and inflammatory pain as TrkA is part of a master control system in the spread of inflammation and pain. As a target, the inhibition of TrkA receptor has the potential to be applicable for the treatment of various forms of chronic pain as well as other pathological conditions associated with inflammation and persistent pain. BXL1H5 is a monoclonal antibody that binds specifically to TrkA receptors. The significant and long-lasting analgesic effects of BXL1H5 have been demonstrated in several animal models.

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.], Metabolic Disorders [diabetes, etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres.

About Lay Line Genomics S.p.A

Lay Line Genomics (LLG) is a private biotechnology company focused on the discovery and development of new drugs and innovative therapies for Alzheimer's and other neurological diseases. Founded in 2001 as a spin out of the International School of Advanced Studies (SISSA) in Trieste, LLG has developed an innovative pipeline of biopharmaceuticals to take into clinical development.

####

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India
Tel: [+91-22-] 40189919 / 40189993
e-mail : media@glenmarkpharma.com